Intralipid Drug Interactions: What to Avoid and What to Tell Your Doctor

Intralipid is an IV fat emulsion, and while it may not have as many well-recognized drug interactions as some oral medications, there are important interactions your healthcare team needs to know about. Many interactions relate to either the lipid content of Intralipid itself or the broader context of parenteral nutrition (PN) and critical care settings where it is most commonly used.

Vitamin K and Anticoagulants (Warfarin) — Moderate Interaction

Intralipid contains a small but measurable amount of vitamin K (approximately 300 micrograms/L). Vitamin K is a cofactor for clotting factor synthesis in the liver, and it directly counteracts the mechanism of warfarin (Coumadin) — an anticoagulant that works by blocking vitamin K-dependent clotting factors.

For patients on warfarin who begin Intralipid therapy (or have their dose changed), INR (International Normalized Ratio) can shift. A consistent Intralipid regimen usually allows for stable warfarin dosing, but any change in Intralipid dose or frequency requires more frequent INR monitoring and possible warfarin dose adjustment.

What to do: Tell your provider if you take warfarin or any anticoagulant. Monitor INR closely when starting, stopping, or changing Intralipid doses.

Propofol — Moderate Interaction (Overlapping Lipid Load)

Propofol is a widely used IV sedative in ICU and surgical settings. Critically, propofol is formulated in a 10% soybean oil emulsion — the same type of fat as Intralipid. This means that patients receiving propofol are also receiving fat calories (1.1 kcal/mL of propofol).

If a patient on propofol also receives Intralipid without accounting for propofol's lipid content, the total fat load can exceed the maximum safe dose of 3 g fat/kg/24 hours — potentially causing fat overload syndrome, hypertriglyceridemia, or PNALD.

What to do: Always inform your ICU team or pharmacist if you are receiving both propofol and Intralipid. The lipid calories from propofol must be subtracted from the Intralipid dose. Your clinical pharmacist will calculate this.

Insulin — Minor to Moderate Interaction

PN is a glucose-rich infusion that requires careful insulin management in diabetic patients and those with stress hyperglycemia in the ICU. The lipid component (Intralipid) interacts indirectly with insulin by contributing to overall caloric load and affecting insulin sensitivity.

Additionally, insulin can be added directly to some PN bags, but it should not be added directly to Intralipid — insulin stability and compatibility require it to be added to the full TPN admixture under the direction of a pharmacist.

What to do: Tell your provider if you have diabetes, use insulin, or have a history of high blood sugars. Blood glucose monitoring is standard during PN initiation and dose changes.

Heparin — Minor Interaction

Heparin (used for blood clot prevention, often as a flush for central lines) can activate lipoprotein lipase, which rapidly breaks down fat particles in the bloodstream. This can transiently increase plasma-free fatty acid levels when heparin is given along with Intralipid. While generally not clinically significant, it can affect triglyceride measurements drawn shortly after heparin flush administration.

What to do: When drawing triglyceride levels for monitoring, draw before heparin flushes when possible, or note timing relative to heparin use on the lab order.

Immunosuppressants — Minor Interaction

Cyclosporine and tacrolimus (immunosuppressants used in transplant patients) are highly lipophilic drugs — meaning they bind to fats. When large amounts of IV lipid are infused, it can theoretically affect the distribution and clearance of these drugs. While not a well-characterized clinical interaction for Intralipid specifically, transplant patients on PN should have immunosuppressant drug levels monitored carefully.

Lab Interference — Important Clinical Consideration

Intralipid can cause transient lipemia (milky blood due to high triglycerides) for 6-12 hours after infusion. This lipemia can interfere with laboratory test results, falsely elevating or lowering:

Bilirubin levels (falsely elevated)

Hemoglobin/hematocrit readings

Coagulation tests (PT/INR) — which is particularly important for patients on warfarin

Electrolyte panel readings (sodium in particular — pseudohyponatremia)

What to do: Draw critical blood work before Intralipid infusion begins or at least 6-12 hours after the infusion is complete.

What to Tell Your Doctor Before Starting Intralipid

Always disclose to your provider:

All prescription medications, including anticoagulants, immunosuppressants, and insulin

Any allergies to eggs, soybeans, or peanuts (contraindications to Intralipid)

History of hypertriglyceridemia or pancreatitis

Kidney disease (increases risk of aluminum toxicity from PN)

Liver disease (affects lipid metabolism and PNALD risk)

For more on Intralipid's side effect profile, see: Intralipid Side Effects: What to Expect and When to Call Your Doctor.